Integrative approach with leading providers Gennev and Midi Health to advance equitable and accessible workplace support for individuals experiencing menopause symptoms Integrative approach with leading providers Gennev and Midi Health to advance equitable and accessible workplace support for individuals experiencing menopause symptoms

Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance

54 Valvoline Instant Oil Change℠ locations in New England are participating in “A Chance for Kids & Families®” program for the 10th consecutive year to raise money for the Jimmy Fund 54 Valvoline Instant Oil Change℠ locations in New England are participating in “A Chance for Kids & Families®” program for the 10th consecutive year to raise money for the Jimmy Fund

-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024 -A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024

WAYNE, Pa., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the U.S Food and Drug Administration (FDA) has cleared the QuikClot Control+™ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy. This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.

Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics

HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract with clinical trial results of its innate cell engager (ICE®) AFM24 in combination with NKGen Biotech’s SNK01 (autologous non-genetically modified NK cells), has been accepted for a poster presentation at the ASCO Breakthrough conference from 3-5 August 2023 in Yokohama, Japan. The presentation includes dose escalation phase data on safety and efficacy of the phase 1 study in patients with advanced or metastatic EGFR-expressing solid tumors (NCT05099549).

Cidara’s U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™

New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.